Cellebrite DI Ltd. (NASDAQ:CLBT – Get Free Report) was the target of some unusual options trading on Tuesday. Traders bought 20,138 call options on the stock. This is an increase of 2,374% compared to the average daily volume of 814 call options.
Analysts Set New Price Targets
A number of equities analysts have recently weighed in on the stock. Lake Street Capital lowered their price target on shares of Cellebrite DI from $21.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. Weiss Ratings cut shares of Cellebrite DI from a “sell (d+)” rating to a “sell (d)” rating in a research note on Thursday, August 27th. Needham & Company LLC decreased their price objective on shares of Cellebrite DI from $15.00 to $12.50 and set a “buy” rating on the stock in a report on Friday, August 14th. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $20.00 to $16.00 and set an “overweight” rating on the stock in a research report on Friday, August 14th. Finally, DA Davidson reaffirmed a “buy” rating and issued a $15.00 target price on shares of Cellebrite DI in a report on Tuesday, September 15th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.70.
Check Out Our Latest Research Report on Cellebrite DI
Cellebrite DI Price Performance
CLBT traded down $0.21 during midday trading on Tuesday, reaching $12.48. 1,492,180 shares of the company’s stock were exchanged, compared to its average volume of 2,236,020. The stock has a market capitalization of $3.11 billion, a PE ratio of 56.70, a P/E/G ratio of 1.91 and a beta of 1.06. The business’s 50-day moving average price is $11.59 and its 200 day moving average price is $13.30. Cellebrite DI has a 1-year low of $9.58 and a 1-year high of $19.98.
Insiders Place Their Bets
In related news, CMO David Gee sold 4,323 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $11.36, for a total transaction of $49,109.28. Following the transaction, the chief marketing officer owned 135,281 shares of the company’s stock, valued at $1,536,792.16. This represents a 3.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas E. Hogan sold 25,299 shares of the stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $11.29, for a total value of $285,625.71. Following the completion of the transaction, the insider owned 765,249 shares of the company’s stock, valued at $8,639,661.21. The trade was a 3.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 196,870 shares of company stock valued at $2,797,143 over the last 90 days. 5.70% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Ground Swell Capital LLC purchased a new position in Cellebrite DI during the third quarter worth about $128,000. King Luther Capital Management Corp boosted its stake in Cellebrite DI by 28.6% in the 3rd quarter. King Luther Capital Management Corp now owns 829,337 shares of the company’s stock worth $9,338,000 after buying an additional 184,290 shares during the last quarter. Capelight Capital Asset Management LP purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $844,000. Parthenon LLC purchased a new stake in Cellebrite DI in the 3rd quarter valued at about $837,000. Finally, Elevation Wealth Partners LLC increased its stake in shares of Cellebrite DI by 93.3% during the 3rd quarter. Elevation Wealth Partners LLC now owns 5,833 shares of the company’s stock valued at $66,000 after acquiring an additional 2,816 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.
About Cellebrite DI
Cellebrite DI Ltd. develops digital intelligence software and services that help organizations access, collect, preserve and analyze digital evidence. Its tools are used to investigate information from mobile devices, computers, cloud sources and other digital systems.
The company’s offerings include its UFED platform for extracting data from digital devices, Physical Analyzer for examining and interpreting evidence, and analytics and case-management tools such as Pathfinder and Guardian.
Featured Articles
- Five stocks we like better than Cellebrite DI
- DraftKings Just Lost 20%—And Its Biggest Gamble Is Still Ahead
- Barrick’s Earnings Beat Could Be Overshadowed by an Even Bigger Opportunity
- Axon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?
- Wall Street May Be Making a Big Mistake With monday.com Stock
Receive News & Ratings for Cellebrite DI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellebrite DI and related companies with MarketBeat.com's FREE daily email newsletter.
